Stocks › MDGL
MADRIGAL PHARMACEUTICALS, INC.
MDGL·Nasdaq·
United States·USD
United States·USD$496.45
+2.83 (+0.57%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
MDGL
MADRIGAL PHARMACEUTICALS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
MDGLS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of MDGL by members of U.S. Congress · 1 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Daniel S. GoldmanHouse · D · NY |
MDGLMADRIGAL PHARMACEUTICALS, INC. · Stock |
Sale $1,001 - $15,000 |
May 19, 2023 | Apr 10, 2023 | Filing ↗ |
Whale Activity
Position changes in MDGL reported for 2026-06-30 by 14 tracked institutional filers
- Increased4
- New1
- Held0
- Decreased4
- Closed1
- No prior filing4
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 1.2M | $644.8M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 835.7K | $448.7M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 781.7K | $419.8M | decreased |
| CITADEL ADVISORS LLC | 507.2K | $272.4M | increased |
| Point72 Asset Management, L.P. | 137.0K | $73.6M | decreased |
| MILLENNIUM MANAGEMENT LLC | 81.2K | $43.6M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 45.9K | $24.7M | decreased |
| Affinity Asset Advisors, LLC | 40.0K | $21.5M | — |
| D. E. Shaw & Co., Inc. | 35.1K | $18.8M | increased |
| Seven Fleet Capital Management LP | 4,973 | $2.7M | — |
| Palo Alto Investors LP | 1,787 | $960K | — |
| Kachkovsky & Fisher, Inc. | 800 | $430K | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by MDGL insiders, by quarter · Form 4
Recent Insider Transactions
953 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Sibold William JohnPresident and CEO · Director | Sale | −761 | $544.83 | $415K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −687 | $540.59 | $371K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −60 | $533.09 | $32K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −368 | $541.64 | $199K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −218 | $535.94 | $117K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −160 | $537.62 | $86K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −1,539 | $544.02 | $837K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −1,202 | $542.60 | $652K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −120 | $546.38 | $66K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −106 | $534.06 | $57K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −644 | $535.27 | $345K | Sep 9, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −640 | $537.17 | $344K | Sep 9, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −522 | $530.23 | $277K | Sep 9, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −520 | $538.30 | $280K | Sep 9, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −512 | $533.09 | $273K | Sep 9, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −505 | $540.19 | $273K | Sep 9, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −396 | $534.20 | $212K | Sep 9, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −368 | $531.99 | $196K | Sep 9, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −362 | $541.65 | $196K | Sep 9, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −347 | $529.27 | $184K | Sep 9, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding MDGL · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 585.0K | $314.1M | 0.01% | Jun 30, 2026 |
| VANGUARD HEALTH CARE FUND VANGUARD SPECIALIZED FUNDS | 563.1K | $263.2M | 0.69% | Jul 31, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 423.1K | $227.2M | 0.12% | Jun 30, 2026 |
| iShares Russell 2000 ETF iSHARES TRUST | 418.0K | $218.8M | 0.30% | Mar 31, 2026 |
| Janus Henderson Forty Fund Janus Investment Fund | 338.6K | $181.8M | 0.76% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 243.7K | $130.8M | 0.28% | Jun 30, 2026 |
| Janus Henderson Enterprise Fund Janus Investment Fund | 233.3K | $125.3M | 0.56% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 216.9K | $116.5M | 0.12% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 211.3K | $113.4M | 1.06% | Jun 30, 2026 |
| Janus Henderson Contrarian Fund Janus Investment Fund | 168.3K | $90.3M | 1.65% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list MDGL's shares (CUSIP 558868105), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming madrigal pharmaceuticals as client
- MADRIGAL PHARMACEUTICALS, INC.MADRIGAL PHARMACEUTICALS, INC. · 2026 Q2 · MMM, HCR$380K
Filing ↗ - CROSSROADS STRATEGIES, LLCMADRIGAL PHARMACEUTICALS, INC. · 2026 Q2 · MMM, HCR$50K
Filing ↗ - CAPITOL COUNSEL LLCMADRIGAL PHARMACEUTICALS, INC. · 2026 Q2 · HCR, MED, MMM$60K
Filing ↗ - BALLARD PARTNERSMADRIGAL PHARMACEUTICALS, INC. · 2026 Q2 · PHA$120K
Filing ↗ - MADRIGAL PHARMACEUTICALS, INC.MADRIGAL PHARMACEUTICALS, INC. · 2026 Q1 · MMM, HCR$380K
Filing ↗
Government Contracts
Federal awards to madrigal pharmaceuticals · USAspending
$30KAwarded · 1 contract on record
- Department of Veterans AffairsREZDIFFRA 80 MG$30K
Jun 5, 2026 · ↗
U.S. Patents
Recent USPTO applications naming MADRIGAL PHARMACEUTICALS, INC.
No USPTO patent applications found for MADRIGAL PHARMACEUTICALS, INC..
Annual Financials
From MDGL's 10-K filings · XBRL
No annual XBRL figures on record for MDGL. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 1-for-35Reverse splitJul 25, 2016
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureAug 12, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 30, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 17, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 6, 2026
EDGAR ↗
About MADRIGAL PHARMACEUTICALS, INC.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersWEST CONSHOHOCKEN, PA
IncorporatedDE
SEC CIK0001157601 ↗
Former namesMADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP